These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Active and passive Abeta-immunotherapy: preclinical and clinical studies and future directions: part I. Agadjanyan MG; Cribbs DH CNS Neurol Disord Drug Targets; 2009 Mar; 8(1):1-6. PubMed ID: 19275632 [No Abstract] [Full Text] [Related]
5. Amyloid-beta immunotherapy: the hope for Alzheimer disease? Barrera-Ocampo A; Lopera F Colomb Med (Cali); 2016 Dec; 47(4):203-212. PubMed ID: 28293044 [TBL] [Abstract][Full Text] [Related]
6. Treatment of Alzheimer's disease: the beginning of a new era. Schenk D Curr Alzheimer Res; 2006 Jul; 3(3):177. PubMed ID: 16842091 [No Abstract] [Full Text] [Related]
7. [Adaptive immunity to Aβ amyloid peptide in Alzheimer's disease: lessons and perspectives]. Dorothée G; Aucouturier P Med Sci (Paris); 2011 Nov; 27(11):938-40. PubMed ID: 22130019 [No Abstract] [Full Text] [Related]
8. Improved Brain Expression of Anti-Amyloid β scFv by Complexation of mRNA Including a Secretion Sequence with PEG-based Block Catiomer. Perche F; Uchida S; Akiba H; Lin CY; Ikegami M; Dirisala A; Nakashima T; Itaka K; Tsumoto K; Kataoka K Curr Alzheimer Res; 2017; 14(3):295-302. PubMed ID: 27829339 [TBL] [Abstract][Full Text] [Related]
12. beta-peptide immunization: a possible new treatment for Alzheimer disease. Schenk DB; Seubert P; Lieberburg I; Wallace J Arch Neurol; 2000 Jul; 57(7):934-6. PubMed ID: 10891974 [No Abstract] [Full Text] [Related]
13. Combined treatment of amyloid-β₁₋₄₂-stimulated bone marrow-derived dendritic cells plus splenocytes from young mice prevents the development of Alzheimer's disease in APPswe/PSENldE9 mice. Wang F; Liu H; Shen X; Ao H; Moore N; Gao L; Chen L; Hu H; Ma H; Yang Z; Zhai C; Qin J; Zhou G; Peng Y; Feng X; Li R; Liang C Neurobiol Aging; 2015 Jan; 36(1):111-22. PubMed ID: 25085784 [TBL] [Abstract][Full Text] [Related]
14. A beta immunotherapy: Lessons learned for potential treatment of Alzheimer's disease. Schenk DB; Seubert P; Grundman M; Black R Neurodegener Dis; 2005; 2(5):255-60. PubMed ID: 16909006 [TBL] [Abstract][Full Text] [Related]
15. Alzheimer disease: Lessons from immunotherapy for Alzheimer disease. Wang YJ Nat Rev Neurol; 2014 Apr; 10(4):188-9. PubMed ID: 24638135 [No Abstract] [Full Text] [Related]
16. Lessons from Anti-Amyloid-β Immunotherapies in Alzheimer Disease: Aiming at a Moving Target. Wang Y; Yan T; Lu H; Yin W; Lin B; Fan W; Zhang X; Fernandez-Funez P Neurodegener Dis; 2017; 17(6):242-250. PubMed ID: 28787714 [TBL] [Abstract][Full Text] [Related]
17. Beta-amyloidbased immunotherapy as a treatment of Alzheimers disease. Solomon B Drugs Today (Barc); 2007 May; 43(5):333-42. PubMed ID: 17724499 [TBL] [Abstract][Full Text] [Related]
19. Translating research on brain aging into public health: a new type of immunotherapy for Alzheimer's disease. Lannfelt L; Pettersson FE; Nilsson LN Nutr Rev; 2010 Dec; 68 Suppl 2():S128-34. PubMed ID: 21091946 [TBL] [Abstract][Full Text] [Related]
20. Immunotherapy for Alzheimer's disease. Wang W; Fan L; Xu D; Wen Z; Yu R; Ma Q Acta Biochim Biophys Sin (Shanghai); 2012 Oct; 44(10):807-14. PubMed ID: 22899646 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]